Changes in solubility & absorption kinetics of co-administered medicinal products w/ pH-dependent bioavailability [eg, azole antifungals (ketoconazole, itraconazole & posaconazole), anti-HIV drugs (atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir, rilpivirine), tyrosine kinase inhibitors (erlotinib, dasatinib, nilotinib)].